Novartis' interest in buying Gen-Probe fizzles, WSJ reports

Novartis' appetite for deals is expected to grow in the near future, but the Swiss drug giant ($NVS) may no longer be interested in gobbling up diagnostic test provider Gen-Probe.

After speculation that Novartis' interest in Gen-Probe had waned, sources with knowledge of the deal told the Wall Street Journal that the drug company was no longer seeking a buyout of the San Diego-based diagnostic test maker. The news yesterday put a dent in Gen-Probe's stock price, which fell 2.47% to $62.41 per share.

Novartis drops out of the picture as a likely buyer of Gen-Probe--which makes diagnostic tests for HIV and other infectious diseases--after the drug maker's CEO Joe Jimenez revealed earlier this month that his company's first priority before seeking more deals is to pay down $22 billion in debt. Yet the pharma chief has been vocal about his interest in potential buyouts of diagnostic companies as the firm seeks new ways to grow its revenue stream.

Sources have said that the Gen-Probe deal might have become too rich for some of its potential suitors, with a price tag of more than $3 billion. And Life Technologies and Thermo Fisher Scientific were already scratched as suitors for Gen-Probe before Novartis lost interest. Yet the WSJ reported that Gen-Probe's sales process continues and another potential bidder could pop onto the radar.

- check out the WSJ report
- see Reuters' article

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.